Browse Studies — Arctuva

Phase 1

A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with ref…

SLE (Systemic Lupus)Lupus Erythematosus, SystemicLupus Nephritis+4 more

Estimated

~$10 – $8,750

CRISPR TherapeuticsNCT06925542

Phase 2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus …

Cutaneous Lupus Erythematosus (CLE)Systemic Lupus ErythematosusSLE+2 more

Estimated

~$10 – $8,750

Ventus Therapeutics U.S., Inc.NCT07260877

Phase 1

A Phase 1a/b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of NTR-1011 in Healthy Adults and Adult Patients With Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)

The goal of this clinical trial is to inform the safety and tolerability of NTR-1011 in treating adult patients diagnosed with systemic lupus erythematosus (SL…

SLE (Systemic Lupus)RA - Rheumatoid Arthritis

Estimated

~$10 – $7,500

NeutrolisNCT07237659

Phase 1

A Phase 1b, Open-label, Pilot Study of CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)

Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).

SLESLE (Systemic Lupus)

Estimated

~$10 – $8,750

Cullinan Therapeutics Inc.NCT06613360